GT200400076A - Ligandos de receptores de cannabinoides y sus usos - Google Patents
Ligandos de receptores de cannabinoides y sus usosInfo
- Publication number
- GT200400076A GT200400076A GT200400076A GT200400076A GT200400076A GT 200400076 A GT200400076 A GT 200400076A GT 200400076 A GT200400076 A GT 200400076A GT 200400076 A GT200400076 A GT 200400076A GT 200400076 A GT200400076 A GT 200400076A
- Authority
- GT
- Guatemala
- Prior art keywords
- cannabinoid
- receiver links
- compounds
- useful
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
LA PRESENTE INVENCIONSE RELACIONA CON COMPUESTOS DE FORMULA (I), QUE SON UTILES EN EL TRATAMIENTO DEL LA ENFERMEDAD DE ALZHEIMER Y OTRAS ENFERMEDADES SIMILARES, ESTOS COMPUESTOS INCLUYEN INHIBIDORES DE LA ENZIMA BETASECRETASA QUE ES UTIL EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER Y OTRAS ENFERMEDADES CARACTERIZADAS POR DEPOSICION DE UN PEPTIDO BETA EN UN MAMIFERO. LOS COMPUESTOS DE UAN INVENCION SON TAMBIEN EN COMPOSICIONES FARMACEUTICAS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46490803P | 2003-04-23 | 2003-04-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT200400076A true GT200400076A (es) | 2004-12-16 |
Family
ID=33310977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT200400076A GT200400076A (es) | 2003-04-23 | 2004-04-20 | Ligandos de receptores de cannabinoides y sus usos |
Country Status (31)
Country | Link |
---|---|
US (1) | US20040214856A1 (es) |
EP (1) | EP1622903B1 (es) |
JP (1) | JP2006524225A (es) |
KR (1) | KR20060006048A (es) |
CN (1) | CN1809566A (es) |
AP (1) | AP2005003427A0 (es) |
AR (1) | AR044037A1 (es) |
AT (1) | ATE409700T1 (es) |
AU (1) | AU2004232552A1 (es) |
BR (1) | BRPI0409791A (es) |
CA (1) | CA2521538A1 (es) |
CL (1) | CL2004000827A1 (es) |
CO (1) | CO5640084A2 (es) |
DE (1) | DE602004016839D1 (es) |
EA (1) | EA200501504A1 (es) |
EC (1) | ECSP056117A (es) |
ES (1) | ES2309517T3 (es) |
GT (1) | GT200400076A (es) |
IS (1) | IS8054A (es) |
MA (1) | MA27766A1 (es) |
MX (1) | MXPA05011454A (es) |
NL (1) | NL1026027C2 (es) |
NO (1) | NO20055516L (es) |
OA (1) | OA13047A (es) |
PA (1) | PA8600601A1 (es) |
PE (1) | PE20050419A1 (es) |
TN (1) | TNSN05272A1 (es) |
TW (1) | TW200510419A (es) |
UY (1) | UY28276A1 (es) |
WO (1) | WO2004094421A1 (es) |
ZA (1) | ZA200508568B (es) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2294330T3 (es) * | 2002-08-02 | 2008-04-01 | MERCK & CO., INC. | Derivados de furo(2,3-b)piridina sustituidos. |
WO2004029204A2 (en) | 2002-09-27 | 2004-04-08 | Merck & Co., Inc. | Substituted pyrimidines |
US7094572B2 (en) * | 2003-03-14 | 2006-08-22 | Bristol-Myers Squibb | Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74 |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) * | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
JP4041153B2 (ja) * | 2003-05-07 | 2008-01-30 | ファイザー・プロダクツ・インク | カンナビノイド受容体リガンドとその使用 |
US7232823B2 (en) * | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US20050026983A1 (en) * | 2003-07-30 | 2005-02-03 | Pfizer Inc | Imidazole compounds and uses thereof |
JP2007510649A (ja) * | 2003-11-04 | 2007-04-26 | メルク エンド カムパニー インコーポレーテッド | 置換ナフチリジノン誘導体 |
US7151097B2 (en) * | 2003-11-07 | 2006-12-19 | Pfizer Inc. | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
JP2008501758A (ja) | 2004-06-09 | 2008-01-24 | グラクソ グループ リミテッド | ピロロピリジン誘導体 |
US20060025448A1 (en) | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
ATE495742T1 (de) * | 2004-10-27 | 2011-02-15 | Janssen Pharmaceutica Nv | Tetrahydro pyridinyl pyrazole cannabinoid modulatoren |
ES2333243T3 (es) * | 2004-12-17 | 2010-02-18 | Eli Lilly And Company | Derivados de tiazolopiridinona como antagonistas del receptor de mch. |
CA2603104A1 (en) * | 2005-03-31 | 2006-10-12 | Janssen Pharmaceutica N.V. | Tetrahydrothiopyrano pyrazole cannabinoid modulators |
WO2006111849A1 (en) * | 2005-04-20 | 2006-10-26 | Pfizer Products Inc. | Acylaminobicyclic heteromatic compounds as cannabinoid receptor ligands |
EP1890767A2 (en) * | 2005-05-27 | 2008-02-27 | Pfizer Products Inc. | Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss |
EA200800562A1 (ru) * | 2005-08-09 | 2008-06-30 | Глаксо Груп Лимитед | Производные имидазопиридина в качестве лигандов каннабиноидного рецептора |
EP1951678A1 (en) * | 2005-10-21 | 2008-08-06 | Mitsubishi Tanabe Pharma Corporation | Pyrazole compounds having cannabinoid receptor (cb1) antagonizing activity |
JP2009528999A (ja) * | 2006-02-21 | 2009-08-13 | アンプラ ファーマシューティカルズ インコーポレイテッド | Cb1アンタゴニストおよび逆アゴニスト |
MX2009001043A (es) | 2006-08-08 | 2009-02-06 | Sanofi Aventis | Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para preparalas, medicamentos que comprenden estos compuestos y su uso. |
WO2008039863A2 (en) * | 2006-09-27 | 2008-04-03 | Braincells, Inc. | Composition comprising a melanocortin receptor (mcr) modulating agent alone or in combination with a second neurogenic agent for treating nervous system disorders |
PE20090142A1 (es) * | 2007-04-11 | 2009-02-19 | Merck & Co Inc | Derivados de furo[2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1 |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2009097995A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
AR072707A1 (es) | 2008-07-09 | 2010-09-15 | Sanofi Aventis | Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos |
JO2870B1 (en) | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
ES2443016T3 (es) | 2009-08-26 | 2014-02-17 | Sanofi | Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo |
WO2011037793A1 (en) | 2009-09-25 | 2011-03-31 | Merck Sharp & Dohme Corp. | Substituted aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120057A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US9365576B2 (en) | 2012-05-24 | 2016-06-14 | Novartis Ag | Pyrrolopyrrolidinone compounds |
EP2948453B1 (en) | 2013-01-22 | 2017-08-02 | Novartis AG | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
EP2948451B1 (en) | 2013-01-22 | 2017-07-12 | Novartis AG | Substituted purinone compounds |
WO2014191894A1 (en) * | 2013-05-27 | 2014-12-04 | Novartis Ag | Imidazopyrrolidinone derivatives and their use in the treatment of disease |
AU2014272700B2 (en) | 2013-05-28 | 2016-12-01 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease |
EA028175B1 (ru) | 2013-05-28 | 2017-10-31 | Новартис Аг | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания |
KR20160086930A (ko) | 2013-11-21 | 2016-07-20 | 노파르티스 아게 | 피롤로피롤론 유도체 및 bet 억제제로서의 그의 용도 |
SG10202006688RA (en) * | 2016-03-11 | 2020-08-28 | Ac Immune Sa | Bicyclic compounds for diagnosis and therapy |
CN105878251B (zh) * | 2016-04-22 | 2019-04-09 | 上海市同济医院 | 帕金森病动物模型的制备方法及其用途 |
WO2018222598A1 (en) | 2017-05-31 | 2018-12-06 | Chemocentryx, Inc. | 6-5 FUSED RINGS AS C5a INHIBITORS |
WO2018222601A1 (en) | 2017-05-31 | 2018-12-06 | Chemocentryx, Inc. | 5-5 FUSED RINGS AS C5a INHIBITORS |
CN111788184B (zh) | 2017-12-22 | 2023-12-22 | 凯莫森特里克斯股份有限公司 | 用作C5aR抑制剂的二芳基取代的5,5-稠合环化合物 |
EP3728203B1 (en) * | 2017-12-22 | 2024-03-13 | ChemoCentryx, Inc. | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS |
EP3773563A4 (en) * | 2018-04-02 | 2021-12-29 | ChemoCentryx, Inc. | Prodrugs of fused-bicyclic c5ar antagonists |
WO2021224489A1 (en) * | 2020-05-07 | 2021-11-11 | Ac Immune Sa | Novel compounds for diagnosis |
WO2022258052A1 (zh) * | 2021-06-11 | 2022-12-15 | 劲方医药科技(上海)有限公司 | 杂环内酰胺类化合物,其制法与医药上的用途 |
AU2022325748A1 (en) * | 2021-08-11 | 2024-02-22 | Landos Biopharma, Inc. | Tetrahydropyrazolopyridine-analog ligands of nlrx1 and uses thereof |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3365459A (en) * | 1964-09-08 | 1968-01-23 | Ciba Geigy Corp | Certain tetrahydro pyrazolo-pyridine and pyrazolo-piperidine derivatives |
US3340269A (en) * | 1964-09-08 | 1967-09-05 | Ciba Geigy Corp | 1-substituted 4-acyl-2, 3-dioxo-piperidine |
GB8613591D0 (en) * | 1986-06-04 | 1986-07-09 | Roussel Lab Ltd | Chemical compounds |
EP0268554B1 (de) * | 1986-10-22 | 1991-12-27 | Ciba-Geigy Ag | 1,5-Diphenylpyrazol-3-carbonsäurederivate zum Schützen von Kulturpflanzen |
PH27357A (en) * | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
FR2665898B1 (fr) * | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2714057B1 (fr) * | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
US5596106A (en) * | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
FR2741621B1 (fr) * | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
FR2742148B1 (fr) * | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
JP2001508799A (ja) * | 1997-01-21 | 2001-07-03 | スミスクライン・ビーチャム・コーポレイション | 新規カンナビノイド受容体モジュレータ |
FR2758723B1 (fr) * | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
FR2761266B1 (fr) * | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates |
IL141769A0 (en) * | 1998-09-11 | 2002-03-10 | Aventis Pharma Sa | Azetidine derivatives, preparation and medicines containing them |
FR2789079B3 (fr) * | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
CA2399791A1 (en) * | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
US6479479B2 (en) * | 2000-03-03 | 2002-11-12 | Aventis Pharma S.A. | Azetidine derivatives, their preparation and pharmaceutical compositions containing them |
US6355631B1 (en) * | 2000-03-03 | 2002-03-12 | Aventis Pharma S.A. | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation |
US6566356B2 (en) * | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
MXPA02009258A (es) * | 2000-03-23 | 2005-04-19 | Solvay Pharm Bv | Derivados de 4,5-dihidro-1h-pirazol que tienen actividad antagonistica de cannabis-1. |
US20020019421A1 (en) * | 2000-07-05 | 2002-02-14 | Roni Biberman | Compositions and therapy for substance addiction |
US20020091114A1 (en) * | 2000-10-04 | 2002-07-11 | Odile Piot-Grosjean | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
AU2002319627A1 (en) * | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
US6509367B1 (en) * | 2001-09-22 | 2003-01-21 | Virginia Commonwealth University | Pyrazole cannabinoid agonist and antagonists |
US20030139386A1 (en) * | 2001-12-21 | 2003-07-24 | Sophie Cote | Pharmaceutical compositions based on azetidine derivatives |
US6825209B2 (en) * | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
WO2004035566A1 (en) * | 2002-10-18 | 2004-04-29 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
US7129239B2 (en) * | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) * | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US7329658B2 (en) * | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7176210B2 (en) * | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7268133B2 (en) * | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) * | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7145012B2 (en) * | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
-
2004
- 2004-04-12 US US10/823,152 patent/US20040214856A1/en not_active Abandoned
- 2004-04-13 DE DE602004016839T patent/DE602004016839D1/de not_active Expired - Fee Related
- 2004-04-13 MX MXPA05011454A patent/MXPA05011454A/es unknown
- 2004-04-13 WO PCT/IB2004/001357 patent/WO2004094421A1/en active IP Right Grant
- 2004-04-13 JP JP2006506562A patent/JP2006524225A/ja not_active Abandoned
- 2004-04-13 AU AU2004232552A patent/AU2004232552A1/en not_active Abandoned
- 2004-04-13 KR KR1020057020010A patent/KR20060006048A/ko not_active Application Discontinuation
- 2004-04-13 CN CNA2004800175674A patent/CN1809566A/zh active Pending
- 2004-04-13 ES ES04727076T patent/ES2309517T3/es not_active Expired - Lifetime
- 2004-04-13 EP EP04727076A patent/EP1622903B1/en not_active Expired - Lifetime
- 2004-04-13 AT AT04727076T patent/ATE409700T1/de not_active IP Right Cessation
- 2004-04-13 CA CA002521538A patent/CA2521538A1/en not_active Abandoned
- 2004-04-13 EA EA200501504A patent/EA200501504A1/ru unknown
- 2004-04-13 BR BRPI0409791-2A patent/BRPI0409791A/pt not_active IP Right Cessation
- 2004-04-13 OA OA1200500291A patent/OA13047A/en unknown
- 2004-04-13 AP AP2005003427A patent/AP2005003427A0/xx unknown
- 2004-04-16 CL CL200400827A patent/CL2004000827A1/es unknown
- 2004-04-20 PE PE2004000389A patent/PE20050419A1/es not_active Application Discontinuation
- 2004-04-20 PA PA20048600601A patent/PA8600601A1/es unknown
- 2004-04-20 GT GT200400076A patent/GT200400076A/es unknown
- 2004-04-21 AR ARP040101339A patent/AR044037A1/es unknown
- 2004-04-21 UY UY28276A patent/UY28276A1/es not_active Application Discontinuation
- 2004-04-22 TW TW093111297A patent/TW200510419A/zh unknown
- 2004-04-23 NL NL1026027A patent/NL1026027C2/nl not_active IP Right Cessation
-
2005
- 2005-09-29 IS IS8054A patent/IS8054A/is unknown
- 2005-10-21 ZA ZA200508568A patent/ZA200508568B/en unknown
- 2005-10-21 MA MA28565A patent/MA27766A1/fr unknown
- 2005-10-21 CO CO05106974A patent/CO5640084A2/es not_active Application Discontinuation
- 2005-10-21 EC EC2005006117A patent/ECSP056117A/es unknown
- 2005-10-21 TN TNP2005000272A patent/TNSN05272A1/fr unknown
- 2005-11-22 NO NO20055516A patent/NO20055516L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MA27766A1 (fr) | 2006-02-01 |
CN1809566A (zh) | 2006-07-26 |
EP1622903B1 (en) | 2008-10-01 |
AU2004232552A1 (en) | 2004-11-04 |
EP1622903A1 (en) | 2006-02-08 |
CO5640084A2 (es) | 2006-05-31 |
ECSP056117A (es) | 2006-03-01 |
CA2521538A1 (en) | 2004-11-04 |
AR044037A1 (es) | 2005-08-24 |
TNSN05272A1 (fr) | 2007-07-10 |
UY28276A1 (es) | 2004-11-30 |
ATE409700T1 (de) | 2008-10-15 |
KR20060006048A (ko) | 2006-01-18 |
ES2309517T3 (es) | 2008-12-16 |
PE20050419A1 (es) | 2005-06-18 |
CL2004000827A1 (es) | 2005-03-04 |
ZA200508568B (en) | 2007-04-25 |
EA200501504A1 (ru) | 2006-04-28 |
NO20055516L (no) | 2005-11-22 |
IS8054A (is) | 2005-09-29 |
WO2004094421A1 (en) | 2004-11-04 |
PA8600601A1 (es) | 2005-05-24 |
US20040214856A1 (en) | 2004-10-28 |
AP2005003427A0 (en) | 2005-12-31 |
JP2006524225A (ja) | 2006-10-26 |
NL1026027A1 (nl) | 2004-10-27 |
OA13047A (en) | 2006-11-10 |
BRPI0409791A (pt) | 2006-05-30 |
MXPA05011454A (es) | 2005-12-12 |
NL1026027C2 (nl) | 2005-07-05 |
DE602004016839D1 (de) | 2008-11-13 |
TW200510419A (en) | 2005-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200400076A (es) | Ligandos de receptores de cannabinoides y sus usos | |
DOP2004000888A (es) | 2-hidroxi-3-diaminoalcanos de benzamida (benzamide 2-hydroxy-3-diaminoalkanes | |
PA8589701A1 (es) | Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer | |
PA8572201A1 (es) | Inhibidores de metaloproteinasa de triaril-oxi-aril-espiro-pirimidina-2,4,6-triona | |
CY1107871T1 (el) | Παραγωγα πυριμιδινης και η χρηση τους ως ρυθμιστων cb2 | |
CY1107956T1 (el) | Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον | |
UY28279A1 (es) | Fenacilo 2 -hidroxi - 3 - diaminoalcanos | |
SV2006002055A (es) | Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos ref. pc32054a | |
BR0314611A (pt) | Compostos de tiazol para o tratamento de distúrbios neurodegenerativos | |
ATE349435T1 (de) | Dpiv-inhibitoren auf glutaminbasis | |
DE60229530D1 (de) | Substituierte piperazine als modulatoren des melanocortinrezeptors | |
UY27918A1 (es) | Derivados de benzodioxol | |
PA8572701A1 (es) | Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida | |
PA8524401A1 (es) | DERIVADOS DE 4-Fenil-piridin | |
PA8583101A1 (es) | Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf) | |
PA8608301A1 (es) | Compuestos heteroarilo de 6 miembros de heteroarilo para el tratamiento de enfermedades neurogenerativas | |
UY28484A1 (es) | Compuestos para el tratamiento de trastornos neurodegenerativos | |
BRPI0411661A (pt) | derivados de n-fenil-piperazina e métodos de profilaxia ou tratamento de doenças associadas com o receptor 5ht 2c | |
DK1831239T5 (da) | Fremgangsmåde til fremstilling af 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta -bismethylen-17alpha-pregn-4-en-3-on-21-carboxylsyre-gamma-lacton og nøgle-mellemprodukter til denne fremgangsmåde | |
SE9901077D0 (sv) | Novel use | |
DE60222286D1 (de) | Verfahren zur erhöhung des testosteronspiegels | |
SV2005001840A (es) | Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos - docket 17005 | |
PA8559201A1 (es) | Compuestos azapoliciclicos condensados con arilo | |
EA200600115A1 (ru) | Производные 2-аминобензойной кислоты | |
PA8601101A1 (es) | 2-hidroxi-3-diaminoalcanos de benzamida |